In GSK's trial of shingles vaccine in China, Shingrix keeps it 100

In October of last year, GSK laid out a plan to double its business in China by 2025, with much of that expansion dependent upon the success of Shingrix, the company’s recombinant zoster vaccine (RZV) to protect older people against shingles.